Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $146,462.00 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Jeffrey Farrow sold 2,186 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $146,462.00. Following the completion of the transaction, the insider directly owned 43,316 shares of the company’s stock, valued at approximately $2,902,172. The trade was a 4.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Tarsus Pharmaceuticals Price Performance

Shares of TARS opened at $64.51 on Friday. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $38.51 and a fifty-two week high of $85.25. The firm’s 50 day moving average price is $69.12 and its 200 day moving average price is $70.30. The company has a market cap of $2.75 billion, a P/E ratio of -39.82 and a beta of 0.55. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The business had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million. On average, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TARS has been the subject of a number of recent research reports. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Guggenheim increased their price target on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $91.83.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the business. TimesSquare Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals in the third quarter valued at $15,898,000. Jennison Associates LLC boosted its position in shares of Tarsus Pharmaceuticals by 5.5% during the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock worth $154,790,000 after acquiring an additional 136,582 shares in the last quarter. TFG Asset Management GP Ltd increased its holdings in shares of Tarsus Pharmaceuticals by 40.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock valued at $10,128,000 after acquiring an additional 71,530 shares during the last quarter. Capricorn Fund Managers Ltd acquired a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter worth about $14,264,000. Finally, Jump Financial LLC lifted its stake in Tarsus Pharmaceuticals by 385.9% during the second quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock worth $9,606,000 after purchasing an additional 188,317 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.